Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy For Subjects With Mild To Moderate Alzheimer's Disease
Condition: Alzheimer's DiseaseInterventions: Drug: Rosiglitazone Extended Release 2mg; Drug: Rosiglitazone Extended Release 8mg; Other: PlaceboSponsors: GlaxoSmithKline; GlaxoSmithKlineCompleted - verified May 2012
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials